A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics
Levodopa is the gold standard treatment for Parkinson’s disease. However, a high unmet medical need exists for longer-lasting oral levodopa formulations to achieve sustained motor improvement with reduced risk of the effect wearing off. In our previous non-clinical studies using rats, more than 3-fo...
Saved in:
Main Authors: | Akane Hayashi, Atsushi Hosomi, Shinsaku Kihara, Masato Nishi, Saori Torisawa, Yoshiumi Ouchi, Hidenori Takada, Junichi Enokizono |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1596139/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of Frégoli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson’s disease undergoing STN-DBS
by: Shunsuke Ogata, et al.
Published: (2025-01-01) -
Buried bumper syndrome in percutaneous endoscopic gastrostomy with a jejunal extension tube in patients undergoing levodopa–carbidopa intestinal gel treatment
by: Masatoshi Nakagawa, et al.
Published: (2023-12-01) -
Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01) -
Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals
by: Yi Rang Han, et al.
Published: (2025-01-01) -
The Influence of pH on the Catalytic Capacity of Levodopa in the Electroreduction Processes of Zn<sup>2+</sup> Ions
by: Jolanta Nieszporek, et al.
Published: (2025-06-01)